US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.36

-0.1100-1.70%

Post-market: 6.360.00000.00%19:30 EDT

Volume:58.07K

Turnover:373.25K

Market Cap:709.20M

PE:-33.42

High:6.67

Open:6.41

Low:6.34

Close:6.47

52wk High:9.42

52wk Low:5.44

Shares:111.51M

Float Shares:35.93M

Volume Ratio:1.43

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1903

EPS(LYR):0.0225

ROE:-17.44%

ROA:-5.42%

PB:6.57

PE(LYR):282.87

Loading ...

Overview Company News Filings

Gyre Therapeutics Inc - Co Through Unit Pans Formal Nda Submission for Hydronidone in Near Future

THOMSON REUTERS

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions

BUZZ-U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences

BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods

BUZZ-Gyre Therapeutics falls on downbeat annual revenue outlook

Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years

BRIEF-Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GUIDANCE: (GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M

MT Newswires Live

Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS

MT Newswires Live

Gyre Therapeutics Q4 revenue rose 33% to USD 37.2 million as Q4 selling and marketing expense climbed 41% to USD 23.8 million

Gyre Therapeutics Inc: Full Year 2026 Revenue Guidance of $100.5 to $111.0 Mln

THOMSON REUTERS

Gyre Therapeutics Inc - Enters Agreement to Buy Cullgen; Deal Expected to Close in Q2 2026

THOMSON REUTERS

Gyre Therapeutics Q4 Revenue USD 37.195 Million

THOMSON REUTERS

Gyre Therapeutics Q4 Operating Profit USD 118 Thousand

THOMSON REUTERS

Gyre Therapeutics Q4 Net Income USD -1.366 Million

THOMSON REUTERS

Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/GYRE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":6.36,"timestamp":1788379200000,"preClose":6.47,"halted":0,"volume":58066,"hourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"19:30 EDT","volume":523,"amount":3326.13,"timestamp":1788391806313,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01700154559505401,"floatShares":35934500,"shares":111509800,"eps":-0.190324,"marketStatus":"Not Yet Opened","change":-0.11,"latestTime":"09-02 16:00:00 EDT","open":6.41,"high":6.67,"low":6.3372,"amount":373253.561039,"amplitude":0.051437,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.190324,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":6.47,"preHourTrading":{"tag":"盘前","latestPrice":6.47,"preClose":6.47,"latestTime":"09:25 EDT","volume":4,"amount":25.88,"timestamp":1788355532163,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.36,"preClose":6.36,"latestTime":"19:30 EDT","volume":523,"amount":3326.13,"timestamp":1788391806313,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.426073,"impliedVol":1.7029,"impliedVolPercentile":0.8611},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":35934500,"roa":"-5.42%","roe":"-17.44%","lyrEps":0.022484,"volumeRatio":1.426073,"shares":111509800,"dividePrice":0,"high":6.67,"amplitude":0.051437,"preClose":6.47,"low":6.3372,"week52Low":5.44,"pbRate":"6.57","psRate":"6.46","week52High":9.42,"institutionHeld":0.2764,"latestPrice":6.36,"eps":-0.190324,"divideRate":0,"volume":58066,"delay":0,"ttmEps":-0.190324,"open":6.41,"prevYearClose":7.06,"prevWeekClose":6.59,"prevMonthClose":6.57,"prevQuarterClose":6.59,"fiveDayClose":6.65,"twentyDayClose":6.23,"sixtyDayClose":6.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"GYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2026-05-07","symbol":"GYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2026-03-12","symbol":"GYRE","fiscalQuarterEnding":"2025/12","expectedEps":0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":0.04},{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760155200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2026-09-01","current":-33.4167,"percent":0.195578,"low":-11548.718266,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"high":193.429414,"avg":-540.923701,"sd":2271.881648,"marketCap":696641822},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-19","current":100.442685,"twenty":-15.279098,"median":-10.179208,"eighty":109.598685,"marketCap":668044300},{"date":"2025-12-26","current":98.256178,"twenty":-15.261711,"median":-10.046352,"eighty":109.489359,"marketCap":653501839},{"date":"2026-01-02","current":96.479641,"twenty":-15.250843,"median":-9.954769,"eighty":109.29804,"marketCap":641686089},{"date":"2026-01-09","current":103.449133,"twenty":-15.243518,"median":-9.652614,"eighty":109.106721,"marketCap":688040184},{"date":"2026-01-16","current":105.22567,"twenty":-15.23799,"median":-9.652614,"eighty":108.560094,"marketCap":699855933},{"date":"2026-01-23","current":110.008655,"twenty":-15.222589,"median":-9.517342,"eighty":109.134052,"marketCap":731667567},{"date":"2026-01-30","current":112.195163,"twenty":-15.163907,"median":-9.314435,"eighty":109.544022,"marketCap":746210028},{"date":"2026-02-06","current":102.629193,"twenty":-15.092184,"median":51.163441,"eighty":109.680679,"marketCap":682586761},{"date":"2026-02-13","current":106.865551,"twenty":-15.037849,"median":54.920332,"eighty":109.544022,"marketCap":710762779},{"date":"2026-02-20","current":115.064954,"twenty":-14.972646,"median":56.469566,"eighty":109.844668,"marketCap":765297008},{"date":"2026-02-27","current":116.431521,"twenty":-14.918384,"median":59.41311,"eighty":110.555282,"marketCap":774386046},{"date":"2026-03-06","current":107.002208,"twenty":-14.903389,"median":60.420111,"eighty":111.484548,"marketCap":711671683},{"date":"2026-03-13","current":141.117848,"twenty":-14.871908,"median":65.067812,"eighty":112.058506,"marketCap":709399423},{"date":"2026-03-20","current":123.520041,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"marketCap":620935247},{"date":"2026-03-27","current":127.879572,"twenty":-14.672715,"median":68.213723,"eighty":113.15176,"marketCap":642850609},{"date":"2026-04-02","current":131.330867,"twenty":-14.637941,"median":68.717439,"eighty":113.9717,"marketCap":660200270},{"date":"2026-04-10","current":131.512514,"twenty":-14.560386,"median":70.412668,"eighty":115.791328,"marketCap":661113410},{"date":"2026-04-17","current":143.501224,"twenty":-14.518403,"median":70.916169,"eighty":118.208058,"marketCap":721380655},{"date":"2026-04-24","current":135.145457,"twenty":-14.464068,"median":71.829251,"eighty":123.520041,"marketCap":679376212},{"date":"2026-05-01","current":139.504988,"twenty":-14.451664,"median":72.980471,"eighty":126.240493,"marketCap":701291573},{"date":"2026-05-08","current":-107.788052,"twenty":-14.451664,"median":73.535777,"eighty":127.334631,"marketCap":685747587},{"date":"2026-05-15","current":-100.534989,"twenty":-14.637941,"median":72.372236,"eighty":126.808829,"marketCap":639603601},{"date":"2026-05-22","current":-88.758033,"twenty":-14.909982,"median":71.342209,"eighty":126.608042,"marketCap":564678607},{"date":"2026-05-29","current":-82.438691,"twenty":-15.079143,"median":70.645053,"eighty":126.314003,"marketCap":524474952},{"date":"2026-06-05","current":-88.901655,"twenty":-15.242525,"median":70.38405,"eighty":126.098579,"marketCap":565592327},{"date":"2026-06-12","current":-87.034576,"twenty":-15.283445,"median":68.648906,"eighty":126.010611,"marketCap":553713974},{"date":"2026-06-18","current":-87.321819,"twenty":-15.377362,"median":68.088818,"eighty":124.946974,"marketCap":555541413},{"date":"2026-06-26","current":-89.47614,"twenty":-15.611553,"median":66.655777,"eighty":123.810677,"marketCap":569247204},{"date":"2026-07-02","current":-93.641161,"twenty":-15.753857,"median":65.067812,"eighty":123.374723,"marketCap":595745068},{"date":"2026-07-10","current":-120.215892,"twenty":-16.183906,"median":60.420111,"eighty":122.720794,"marketCap":764813504},{"date":"2026-07-17","current":-112.505251,"twenty":-16.863516,"median":59.41311,"eighty":121.124631,"marketCap":715758410},{"date":"2026-07-24","current":-105.320337,"twenty":-26.790554,"median":56.469566,"eighty":119.109992,"marketCap":670047982},{"date":"2026-07-31","current":-101.8155,"twenty":-28.630129,"median":54.920332,"eighty":118.134453,"marketCap":647750212},{"date":"2026-08-07","current":-112.154768,"twenty":-30.09916,"median":51.163441,"eighty":117.790204,"marketCap":713528633},{"date":"2026-08-14","current":-32.674966,"twenty":-30.809057,"median":-9.314435,"eighty":117.359023,"marketCap":693460810},{"date":"2026-08-21","current":-35.073129,"twenty":-31.698577,"median":-9.517342,"eighty":116.303482,"marketCap":744357016},{"date":"2026-08-28","current":-33.37443,"twenty":-32.401491,"median":-9.652614,"eighty":115.755379,"marketCap":708305536},{"date":"2026-09-01","current":-32.824851,"twenty":-32.602728,"median":-9.652614,"eighty":115.68348,"marketCap":696641822}],"updateTime":1788414598566},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620442611","title":"Gyre Therapeutics Inc - Co Through Unit Pans Formal Nda Submission for Hydronidone in Near Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442611?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA1KQQBT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620262664","title":"Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262664","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262664?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March  17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257004/0/en/Gyre-Therapeutics-Announces-China-s-NMPA-Grants-Priority-Review-to-the-NDA-for-Hydronidone-F351-for-CHB-Induced-Liver-Fibrosis-Treatment.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","LU1223082196.USD","GYRE","CHB","LU1223082519.USD","LU1223083913.SGD","BK4017","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619417705","title":"Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619417705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619417705?lang=en_us&edition=fundamental","pubTime":"2026-03-15 14:01","pubTimestamp":1773554513,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc (GYRE) has disclosed a new risk, in the Demand category. Gyre Therapeutics Inc. faces the risk that rapid shifts in clinical ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-faces-operational-risk-from-rapid-shifts-in-clinical-demand-and-market-conditions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-faces-operational-risk-from-rapid-shifts-in-clinical-demand-and-market-conditions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619777158","title":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2619777158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619777158?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:59","pubTimestamp":1773331150,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE  -Natera, Pacira BioSciences, Kezar Life SciencesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N40014H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMZ","NTRA","LU1868837565.USD","SM","LU0320765646.SGD","DG","BMBL","AAL","INTS","KKR","BBW","LU1116320737.USD","MELI","SG9999014906.USD","GIII","RPID","TBBK","ARES","WLTH","DOW","DAL","BK4121","OWL","JBL","KZR","LU0175139822.USD","LUV","AALG","CASH","GYRE","CE","UAL","XOMX","CUBI","PCRX","KMLI","SPRC","GFS","MOS","DKS","IE0002270589.USD","XOMO","MUR","BX","CF","SG9999014898.SGD","NOG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618650131","title":"BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods","url":"https://stock-news.laohu8.com/highlight/detail?id=2618650131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618650131?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:52","pubTimestamp":1773316363,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting GoodsWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL6N4000T0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072461881.USD","IE00B64PRP62.GBP","DG","LU2380233275.USD","RPID","BK4139","LUV","LU0320765489.SGD","BK4093","LU1989763690.USD","UAL","BK4211","MOS","LU1430594728.SGD","LU0208291251.USD","BK4141","IE00BGHQF748.EUR","CUBI","AAL","LU0345780950.USD","LU1585245621.USD","DKS","AALG","LU1988902786.USD","LU2264538146.SGD","LU0630314457.HKD","LU0310800965.SGD","DAL","IE0009354923.USD","TBBK","LU0070302665.USD","BK4500","IE00BBT3K403.USD","BK4008","CASH","BX","CF","IE00BLSP4239.USD","LU0162691827.USD","BK4114","IE00BFMHRM44.USD","LU1267930227.SGD","BMBL","IE00B3QW5Z07.USD","GFS","IE00BN8TJ469.HKD","GYRE","LU1064131342.USD","LU0345781412.USD","LU1989763427.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413936","title":"BUZZ-Gyre Therapeutics falls on downbeat annual revenue outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413936","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618413936?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:20","pubTimestamp":1773314435,"startTime":"0","endTime":"0","summary":"BUZZ-Gyre Therapeutics falls on downbeat annual revenue outlook** Shares of biotech firm Gyre Therapeutics GYRE.O fall 6.72% to $7.77 premarket ** Co expects FY26 revenue in the range of $100.5 million to $111 million, below analysts' estimate of $148 million, according to data compiled by LSEG ** Co says it expects 2026 to be a transition period with focus on regulatory activities** Plans to submit a marketing application in China for conditional approval of Hydronidone, its liver fibrosis drug candidate, in 1H 2026** GYRE expects to moderate promotional activities for its newer drugs Contiva and Etorel, amid procurement uncertainties in China ** Posts Q4 revenue of $37.2 million vs analysts' estimate of $35.4 million ** GYRE shares were down over 41% in 2025   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4N4000V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618133126","title":"Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618133126?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:32","pubTimestamp":1773311567,"startTime":"0","endTime":"0","summary":"Gyre said it sees potential liver fibrosis revenue of about USD 400-600 million within five years for Hydronidone , based on patient population data. The company also said it expects ETUARY revenue for lung fibrosis to sustain at about USD 100 million if no competitor markets a generic drug in the near term. Gyre said it sees potential net margins of 20%-25% for its commercial products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL6B3C2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618133893","title":"BRIEF-Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133893","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618133893?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:20","pubTimestamp":1773310847,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results March 12 (Reuters) - Gyre Therapeutics Inc GYRE.O: GYRE THERAPEUTICS Q4 PRETAX PROFIT USD -66 THOUSANDGYRE THERAPEUT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXD1FF5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138452","title":"GUIDANCE: (GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138452","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138452?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:12","pubTimestamp":1773310323,"startTime":"0","endTime":"0","summary":"GUIDANCE: (GYRE) Gyre Therapeutics Expects 2026 Revenue Range $100.5M to $111.0M, vs. FactSet Est of $148.0M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618133138","title":"Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2618133138","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618133138?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:08","pubTimestamp":1773310133,"startTime":"0","endTime":"0","summary":"Earnings Flash (GYRE) Gyre Therapeutics Posts Q4 Loss $0.02 a Share, vs. FactSet Est of $0.06 EPS","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138999","title":"Gyre Therapeutics Q4 revenue rose 33% to USD 37.2 million as Q4 selling and marketing expense climbed 41% to USD 23.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138999?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:07","pubTimestamp":1773310025,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Q4 revenue rose 33% to USD 37.2 million as Q4 selling and marketing expense climbed 41% to USD 23.8 million. Gyre reported Q4 revenue of USD 37.2 million, up 33% year over year, driven by higher ETUARY sales and contributions from Etorel and Contiva launches. Q4 net loss was USD 1.4 million, compared with net income a year earlier, while Q4 selling and marketing expense rose 41% to USD 23.82 million due to expanded commercial activities. For FY2025, revenue increased 10% to USD 116.59 million, including ETUARY sales of USD 106.1 million and initial-year sales of USD 5.5 million for Contiva and USD 4.6 million for Etorel. FY2025 net income was USD 9.88 million, down 45%, as operating expenses rose, including FY selling and marketing expense of USD 65.18 million and general and administrative expense of USD 20.8 million. Gyre guided FY2026 revenue to USD 100.5 million to USD 111 million and said it expects 2026 to be a transition year as it prioritizes regulatory work, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7R6bxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618505138","title":"Gyre Therapeutics Inc: Full Year 2026 Revenue Guidance of $100.5 to $111.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2618505138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618505138?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUAPSFTB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138621","title":"Gyre Therapeutics Inc - Enters Agreement to Buy Cullgen; Deal Expected to Close in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138621?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUAPSFTB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618388411","title":"Gyre Therapeutics Q4 Revenue USD 37.195 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618388411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618388411?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXD1FF5C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138827","title":"Gyre Therapeutics Q4 Operating Profit USD 118 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138827?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXD1FF5C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138826","title":"Gyre Therapeutics Q4 Net Income USD -1.366 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138826?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nPLXD1FF5C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618379138","title":"Press Release: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618379138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618379138?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:00","pubTimestamp":1773309600,"startTime":"0","endTime":"0","summary":"Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range. Full year 2026 revenue guidance of $100.5 to $111.0 million. Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026. Alignment with China's Center for Drug Evaluation  on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application  submission for conditional approval expected in the first half of 2026. Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis  trial. Hydronidone U.S. Investigational New Drug  application for MASH-associated liver fibrosis anticipated in 2026. Fourth Quarter 2025 Business Highlights and Upcoming Milestones","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223082519.USD","R","BK4017","PD","CDE","CHB","BK4022","LU1169590202.USD","LU1169589451.USD","GYRE","BK4023","BK4232","LU1223082196.USD","LU1223083913.SGD","BK4139","IND"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":77,"code":"91000000","status":"200"}]}}